Congratulations to Anita Moser, Head of U.S. Neurology Assets and Optimization, and Erica Puntel, U.S. Neurology and Global Digital Business Transformation Communications Lead, for their recognition as Healthcare Businesswomen's Association (HBA) Rising Stars for 2021.

UCB is passionate about transforming the lives of people living with severe diseases and uncovering the intersections of scientific understanding and patient needs. This May, we are honoring Arthritis Awareness Month and Spondyloarthritis Awareness Month by exploring the impacts of different kinds of arthritis on patients. Learn more about psoriatic arthritis, rheumatoid arthritis, and non-radiographic axial spondyloarthritis, their prevalence, and how individuals living with these diseases are impacted.

UCB is proud to be one of 26 members launching the IP PACT and we invite you to learn more about the commitments we are making to ensure our approach to IP delivers value for society, patients, and UCB.

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021 

At UCB, we have come to develop a deep understanding of the patient experience and the unmet needs of people living with immuno-dermatological conditions. As we join for the American Academy of Dermatology VMX 2021 Conference, read from Rhonda Peebles, our Head of U.S. Dermatology, on UCB’s approach to creating value for patients.

Sustainability is our business approach at UCB. Our goal is to contribute to the transition toward a low-carbon and green economy to protect the planet by developing and producing medicines for people with severe diseases in the most environmentally sustainable way possible. This means reducing our carbon footprint, water consumption, and waste production across the company. This Earth Day, we are highlighting how we’ve progressed in our goal to reduce our local and global environmental impact by 2030, despite the unprecedented events of 2020.

At UCB, we know that fostering a strong employee culture and a rewarding work environment is critical to continuing to innovate for patients living with severe immunological and neurological conditions. Over the past year, the future of where and how we work and collaborate has been put to the test by COVID-19. Read more from Head of U.S. Corporate Affairs, Patty Fritz, on how UCB is reimagining the workplace at our U.S. Headquarters in Atlanta, Georgia.

With more than 20 years of experience in caring for people living with epilepsy, our goal has always been to know and understand the day-to-day experiences of people living with the disease better than anyone. Over the past year this has been especially true, and the challenges we’ve faced have reinvigorated our commitment to the overall emotional and physical well-being of patients. Read more from UCB’s Head of U.S. Neurology, Mike Davis, about how UCB is finding new ways to better connect with patients and improve their day-to-day experience.